89bio News

89bio Analyst Ratings

BenzingaSep 21 00:15

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

BenzingaSep 21 00:15

Leerink Partners Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $34

Futu NewsAug 7 13:32

Buy Rating Affirmed for 89bio: Promising Pegozafermin Trials and Regulatory Confidence

TipRanksAug 7 13:29

89bio Price Target Raised to $53.00/Share From $50.00 by Raymond James

Dow JonesAug 7 01:21

RBC Capital Maintains Sector Perform on 89bio, Lowers Price Target to $12

BenzingaAug 6 20:45

Evercore Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $33

Futu NewsAug 6 20:34

RBC Capital Maintains 89bio(ETNB.US) With Hold Rating, Cuts Target Price to $12

Futu NewsAug 6 19:31

89bio (ETNB) Receives a Hold From RBC Capital

TipRanksAug 6 19:05

HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $29 Price Target

BenzingaAug 6 18:43

89bio Analyst Ratings

BenzingaAug 6 18:43

H.C. Wainwright Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $29

Futu NewsAug 6 18:31

Buy Rating Affirmed for 89bio Amid Promising Pegozafermin Clinical Trials

TipRanksAug 6 18:29

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

BenzingaJul 1 23:07

89bio Analyst Ratings

BenzingaJul 1 23:05

89bio Analyst Ratings

BenzingaJun 18 01:30

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

BenzingaJun 18 01:30

89bio Analyst Ratings

BenzingaJun 13 00:15

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

BenzingaJun 13 00:15

89bio Analyst Ratings

BenzingaJun 11 18:45